Emmanuelle Landmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emmanuelle Landmann has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ada Sera Kurt
Department of Inflammation Biology, Institute of Liver Studies, School of Immunology and Microbial Sciences, James Black Centre, King's College London, London, SE5 9NU, United Kingdom
1 shared publication - Alberto Sanchez-Fueyo
Institute of Liver Studies, King's College London University and King's College Hospital, London, United Kingdom
1 shared publication - Alessandro Sinopoli
Ridgeline Discovery GmbH, Aeschenvorstadt 36, CH-4051, Switzerland
1 shared publication - Amélie Wiederkehr
Ridgeline Discovery GmbH, Aeschenvorstadt 36, CH-4051, Switzerland
1 shared publication - Anna Camus
Laboratory of Organic Chemistry, ETH Zurich, 8093 Zurich, Switzerland
1 shared publication - Anna Devaux
Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 19 September 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 38-47
Conferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation
- 19 September 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 38-47
Open AccessConferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation
- Open Access
- 29 September 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (12)
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Targeted eradication of transformed or otherwise dysregulated cells using monoclonal antibodies (mAb), antibody–drug conjugates (ADC), T cell engagers (TCE), or chimeric antigen receptor (CAR) cells is very effective for hematologic diseases. Unlike the breakthrough progress achieved for B cell malignancies, there is a pressing need to find suitable antigens for myeloid malignancies. CD123, the interleukin-3 (IL-3) receptor alpha-chain, is highly expressed in various hematological malignancies, including acute myeloid leukemia (AML). However, shared CD123 expression on healthy hematopoietic stem and progenitor cells (HSPCs) bears the risk for myelotoxicity. We demonstrate that epitope-engineered HSPCs were shielded from CD123-targeted immunotherapy but remained functional, while CD123-deficient HSPCs displayed a competitive disadvantage. Transplantation of genome-edited HSPCs could enable tumor-selective targeted immunotherapy while rebuilding a fully functional hematopoietic system. We envision that this approach is broadly applicable to other targets and cells, could render hitherto undruggable targets accessible to immunotherapy, and will allow continued posttransplant therapy, for instance, to treat minimal residual disease (MRD).
- 29 September 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (12)
Open AccessEpitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Targeted eradication of transformed or otherwise dysregulated cells using monoclonal antibodies (mAb), antibody–drug conjugates (ADC), T cell engagers (TCE), or chimeric antigen receptor (CAR) cells is very effective for hematologic diseases. Unlike the breakthrough progress achieved for B cell malignancies, there is a pressing need to find suitable antigens for myeloid malignancies. CD123, the interleukin-3 (IL-3) receptor alpha-chain, is highly expressed in various hematological malignancies, including acute myeloid leukemia (AML). However, shared CD123 expression on healthy hematopoietic stem and progenitor cells (HSPCs) bears the risk for myelotoxicity. We demonstrate that epitope-engineered HSPCs were shielded from CD123-targeted immunotherapy but remained functional, while CD123-deficient HSPCs displayed a competitive disadvantage. Transplantation of genome-edited HSPCs could enable tumor-selective targeted immunotherapy while rebuilding a fully functional hematopoietic system. We envision that this approach is broadly applicable to other targets and cells, could render hitherto undruggable targets accessible to immunotherapy, and will allow continued posttransplant therapy, for instance, to treat minimal residual disease (MRD).